Headache

Nile Introduces Industry’s First AI Networking Solution With Performance Guarantees

Retrieved on: 
Tuesday, March 19, 2024
Cloud, NOC, Automation, Organization, Headache, Interest, Growth, Digital, Wi-Fi, Internet of things, SAN, Internet, Network, AI, Software, Digital twin, Architecture, Data collection, Machine learning, Collection, Online shopping

Components of the architecture include Nile Service Blocks, Nile Services Cloud, and two categories of AI applications: Nile Copilot and Nile Autopilot.

Key Points: 
  • Components of the architecture include Nile Service Blocks, Nile Services Cloud, and two categories of AI applications: Nile Copilot and Nile Autopilot.
  • What Nile understands that the rest of the industry has missed is that AI cannot be an incremental addition to an existing architecture.
  • Three core elements enable these comprehensive capabilities: Nile Service Blocks, Nile Services Cloud, and Nile AI Applications.
  • Powered by Nile Service Blocks, Nile Services Cloud, and Nile AI Applications, Nile Access Service is available today and deployed in production networks worldwide.

Duck Creek Technologies Transforms North American Insurers' Connectivity to Preferred Payment Providers with the Launch of Duck Creek Payments 

Retrieved on: 
Tuesday, March 19, 2024
Head, Software as a service, Headache, Software, Insurance, Ecosystem, P&C

Serving as the singular entry point to the global payments ecosystem, Duck Creek Payments ensures insurers enjoy heightened cost efficiency, accelerated time-to-market, improved customer experiences, and future-proofed payment offerings, all while ensuring payment compliance.

Key Points: 
  • Serving as the singular entry point to the global payments ecosystem, Duck Creek Payments ensures insurers enjoy heightened cost efficiency, accelerated time-to-market, improved customer experiences, and future-proofed payment offerings, all while ensuring payment compliance.
  • Initially crafted for the European insurance market, Duck Creek Payments has already solved payment complexities for European clients.
  • “Duck Creek Payments is the key to unlocking a streamlined, future-ready payment experience for insurers, solidifying its status as a game-changer in our industry,” said Jess Keeney, Chief Product & Technology Officer, Duck Creek Technologies.
  • ET to learn more about simplifying payments for carriers with Duck Creek Payments.

Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in

Retrieved on: 
Monday, March 18, 2024
Neurology, Headache, NDS, Patient, Contraindication, Nonsteroidal anti-inflammatory drug, Chronic pain, Migraine, Health Canada, Chemical patent, PALO, OPML, Patent, Therapy, FDA

ELYXYB® (celecoxib oral solution) is in the same class of agents, is fast acting, and has the potential to have the lowest gastrointestinal (GI) side effects of all NSAIDs.3

Key Points: 
  • ELYXYB® (celecoxib oral solution) is in the same class of agents, is fast acting, and has the potential to have the lowest gastrointestinal (GI) side effects of all NSAIDs.3
    The anticipated timeline for approval in Canada is approximately 12 months depending on review cycles and information requests by Health Canada.
  • ELYXYB®’s product profile mapped with a high degree of certainty to these stated unmet needs.
  • For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com .
  • For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com .

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

Retrieved on: 
Friday, March 15, 2024
Nosebleed, Research, Polyp (medicine), Vanderbilt University, Sciatica, Fluticasone, Education, Drainage, Disease, Incidence, Headache, Inflammation, Patient, Conditional sentence, Chronic obstructive pulmonary disease, Sinusitis, CRS, Standard of care, Quality of life, Migraine, Nasal cavity, Ear, ENT, Service, MPH, Nose, OPTN, FDA, Frustration, Food, Pharmaceutical industry

YARDLEY, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the U.S. Food and Drug Administration (FDA) has approved XHANCE® (fluticasone propionate) nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 years of age and older.

Key Points: 
  • Chronic sinusitis (also called “chronic rhinosinusitis” or “CRS”) is one of the most common chronic diseases, affecting approximately 30 million adults in the United States.
  • Research shows that the disease impairs quality of life to a similar degree as other serious chronic conditions, such as chronic obstructive pulmonary disease, sciatica, or migraine.
  • Chronic sinusitis is also one of the most common diagnoses in adult outpatient medicine.
  • Chronic sinusitis is diagnosed in approximately 10 million outpatient visits, of which approximately 70% result in antibiotic prescriptions, and leads to more than 600,000 surgeries annually.

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

Retrieved on: 
Monday, April 1, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Factor D, Arthralgia, Chest pain, Confusion, Neuropsychological test, Infection, Eculizumab, Risk, Headache, ALPHA, PNH, C5, Patient, Orphan, Mitigation, Vaccine, Light, Paroxysmal nocturnal hemoglobinuria, EVH, Bacteria, University, Chills, MD, Breakthrough therapy, Cough, European Medicines Agency, Fatigue, Nausea, Rash, Fever, Priority, Safety, Immune system, REMS, Division, Vomiting, Hematology, Patient safety, Medicine

VOYDEYA has also been granted Orphan Drug Designation in the US, European Union (EU) and Japan for the treatment of PNH.

Key Points: 
  • VOYDEYA has also been granted Orphan Drug Designation in the US, European Union (EU) and Japan for the treatment of PNH.
  • You must complete or update meningococcal vaccine(s) and streptococcus vaccine(s) at least 2 weeks before your first dose of VOYDEYA.
  • If you have been vaccinated against these bacteria in the past, you might need additional vaccinations before starting VOYDEYA.
  • Carry it with you at all times during treatment and for 1 week after your last VOYDEYA dose.

Domo Boosts Flexible Data Foundation with Robust Enhancements to Cloud Amplifier

Retrieved on: 
Thursday, March 28, 2024
Technology, Security, Professional Services, Software, Networks, Internet, Data Analytics, Data Management, Artificial Intelligence, Cloud, Conference, Headache, EVP, BigQuery, AI, Cloud analytics, Business intelligence, Extract, Analysis, MySQL, Cloud computing, Video game

Today Domo (Nasdaq: DOMO) announced at Domopalooza: the AI + Data Conference enhancements to Cloud Amplifier, the company’s multi-cloud data offering, to enable users with the powerful and flexible tools they need to fully integrate with multiple cloud data platforms and deliver actionable AI-driven insights while maintaining the security and governance organizations need.

Key Points: 
  • Today Domo (Nasdaq: DOMO) announced at Domopalooza: the AI + Data Conference enhancements to Cloud Amplifier, the company’s multi-cloud data offering, to enable users with the powerful and flexible tools they need to fully integrate with multiple cloud data platforms and deliver actionable AI-driven insights while maintaining the security and governance organizations need.
  • “Millions of users across these cloud platforms no longer need to pull data out of their native systems to transform, clean and derive value from their data.
  • Given that cloud costs are a key consideration for any modern business, these new Cloud Amplifier settings allow you to control how often Domo communicates with your data cloud, ensuring data meets the needs of the user or organization but is managed in an efficient way to avoid unnecessary costs.
  • For more information on Domo Cloud Amplifier, visit: www.domo.com/platform/leverage-the-cloud

Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Retrieved on: 
Tuesday, March 26, 2024
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Microangiopathic hemolytic anemia, Incidence, Headache, Patient, Thrombotic thrombocytopenic purpura, Constipation, Mortality, Head, TTP, Nausea, Toll, Heart, Safety, Itch, Thrombocytopenia, Hypertension, Pharmaceutical industry

Takeda ( TSE: 4502/NYSE:TAK ) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of ADZYNMA (apadamtase alfa /cinaxadamtase alfa) for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP) for individuals 12 years of age and older.1 ADZYNMA is the first and only approved recombinant ADAMTS13 protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAMTS13 enzyme.

Key Points: 
  • Takeda ( TSE: 4502/NYSE:TAK ) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of ADZYNMA (apadamtase alfa /cinaxadamtase alfa) for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP) for individuals 12 years of age and older.1 ADZYNMA is the first and only approved recombinant ADAMTS13 protein designed to address an unmet medical need in people with cTTP by replacing the deficient ADAMTS13 enzyme.
  • cTTP is an ultra-rare, chronic blood clotting disorder caused by a deficiency in the ADAMTS13 enzyme.2 It is associated with acute events and debilitating chronic symptoms or thrombotic thrombocytopenic purpura (TTP) manifestations, which can include thrombocytopenia, microangiopathic hemolytic anemia, headache and abdominal pain.2,3,4 When left untreated, acute TTP events have a mortality rate of >90%.2,4
    “The approval of ADZYNMA is an important milestone for people living with cTTP in Japan, who had limited treatment options and now have the first treatment option specifically approved to treat this ultra-rare condition,” said Yasushi Kajii, Head, R&D Japan Region at Takeda.
  • “Developing innovative treatments that make a difference in the lives of patients is at the heart of what we do.
  • In Period 3, the incidence of TEAEs was 2.8% (1/36) in this drug group: nausea and headache (1 subject each).6
    This approval does not result in any changes to Takeda’s consolidated forecast for the fiscal year ending March 31, 2024 (FY2023).

Global Balloon Catheter Market Analysis Report 2023-2030: Minimally Invasive Solutions and Age-Associated Cardiovascular Problems Drive Demand - ResearchAndMarkets.com

Retrieved on: 
Friday, March 22, 2024
Medical Supplies, Medical Devices, Health, Surgery, Cardiology, Biotechnology, Coronary artery disease, Balloon catheter, Neurology, Prevalence, Headache, Urbanization, Blood, Peripheral artery disease, Urology, Angioplasty, Nylon, Hospital, Restenosis, Research, Splenic infarction, Telehealth, Heart, Stroke, Artery, Safety, Prognosis, Catheter, FDA, Artificial intelligence, CAD, Ageing, Medical device

The "Global Balloon Catheter Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Balloon Catheter Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The growing prevalence of age-associated cardiovascular problems propels balloon catheter demand, significantly increasing the medical device market and enhancing the care of growing older populations globally.
  • Offering minimally invasive alternatives to conventional surgeries, balloon catheters lead to faster recuperation instances, decreased dangers, and progressed patient effects, driving market increase towards minimally invasive tactics.
  • By product type, the Global Balloon Catheter Market is divided into Normal Balloon Catheter, Drug Eluting Balloon Catheter, Cutting Balloon Catheter, Scoring Balloon Catheter, Stent Graft Balloon Catheter, and Others.

AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Medical Devices, Health, Pharmaceutical, Health Insurance, Diabetes, Blood pressure, Depression, Arrhythmia, Hypokalemia, ICS, Anaphylaxis, Angioedema, Congress, Moyamoya disease, AstraZeneca, MAOI, Hyperthyroidism, Risk, ECG, Incidence, Headache, Immunosuppression, Patient, QT interval, Chronic obstructive pulmonary disease, Inhalation, Chickenpox, Research, Budesonide, System, Liver, Cough, Rash, Infection, Salbutamol, Water, Cataract, Adrenal gland, Measles, Safety, Bronchospasm, COPD, Glaucoma, Use, Catherine Disher, Fatality, Monoamine oxidase inhibitor, Hypertension, Medicine, Pharmaceutical industry

AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.

Key Points: 
  • AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month for their medicine.
  • We remain dedicated to addressing the need for affordability of our medicines, but the system is complex and we cannot do it alone.
  • The Company will continue to provide discounts and rebates off the list price to help patients afford its inhaled respiratory medicines.
  • AstraZeneca remains dedicated to transforming patient outcomes, while ensuring access and affordability of our innovative medicines.

DataGrail’s AI Governance Solution Uncovers Shadow AI & Helps Businesses Innovate with Confidence

Retrieved on: 
Wednesday, March 13, 2024
Apps, Applications, Technology, Mobile, Wireless, Security, Software, Networks, Internet, Data Management, Artificial Intelligence, Microsoft, EEG, Organization, Software as a service, OpenAI, University, Headache, Data mining, Risk, Salesforce, CO, Policy, Classification, AI, PIAS, Overture, Risk assessment, Publication, Data, Yahoo!, Machine learning, Multimedia, Privacy, Medical device

At a time when 48% of CISOs cite AI security as their biggest concern, DataGrail’s AI Governance Solution uncovers AI risks in third-party apps and systems that power their business, helping organizations get the benefits of AI innovation, while understanding and managing its associated risks.

Key Points: 
  • At a time when 48% of CISOs cite AI security as their biggest concern, DataGrail’s AI Governance Solution uncovers AI risks in third-party apps and systems that power their business, helping organizations get the benefits of AI innovation, while understanding and managing its associated risks.
  • View the full release here: https://www.businesswire.com/news/home/20240313437294/en/
    DataGrail’s AI Governance Solution uncovers AI risks in third-party apps and systems that power their business, helping organizations get the benefits of AI innovation, while understanding and managing its associated risks.
  • Available to enterprises and consumer brands, DataGrail provides a framework for businesses to develop their own customized AI principles and policy based on their values.
  • With DataGrail’s AI Governance Solution security and privacy teams can:
    Discover traditional AI and generative AI models in third parties: DataGrail’s Responsible Data Discovery continuously detects AI and generative AI models used throughout an organization's SaaS and third-party systems.